<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02571699</url>
  </required_header>
  <id_info>
    <org_study_id>MGH</org_study_id>
    <nct_id>NCT02571699</nct_id>
  </id_info>
  <brief_title>Minimum Effective Volume of Lidocaine-Bupivacaine for Subgluteal Block</brief_title>
  <official_title>Minimum Effective Volume of Lidocaine-Bupivacaine for Ultrasound-Guided Subgluteal Sciatic Nerve Block</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McGill University Health Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine the minimum effective volume of LA in 90 % of patients
      (MEV90) required for US-guided subgluteal sciatic nerve block.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to determine the minimum effective volume of LA in 90 % of patients
      (MEV90) required for US-guided subgluteal sciatic nerve block.

      Success rate is defined as a minimal composite score of 6 points (out of 8 points) at 30
      minutes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>success rate</measure>
    <time_frame>0-30 minutes</time_frame>
    <description>minimal composite score of 6 out of 8 points</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Injuries to the Ankle and Foot</condition>
  <arm_group>
    <arm_group_label>Subgluteal sciatic block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subgluteal block with similar volume</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subgluteal block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subgluteal block with decreasing volume</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Subgluteal Nerve Block</intervention_name>
    <description>ultrasound-guided subgluteal sciatic nerve block.</description>
    <arm_group_label>Subgluteal sciatic block</arm_group_label>
    <arm_group_label>Subgluteal block</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age between 18 and 75 years

          -  American Society of Anesthesiologists classification 1-3

          -  body mass index between 20 and 35

        Exclusion Criteria:

          -  adults who are unable to give their own consent

          -  pre-existing neuropathy (assessed by history and physical examination)

          -  coagulopathy (assessed by history and physical examination and, if deemed clinically
             necessary, by blood work up i.e. platelets≤ 100, International Normalized Ratio≥ 1.4
             or partial prothrombin time ≥ 50)

          -  renal failure (assessed by history and physical examination and, if deemed clinically
             necessary, by blood work up i.e. creatinine ≥ 100)

          -  hepatic failure (assessed by history and physical examination and, if deemed
             clinically necessary, by blood work up i.e. transaminases ≥ 100)

          -  allergy to LA

          -  pregnancy

          -  prior surgery in the subgluteal region

          -  chronic pain syndromes requiring opioid intake at home
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>De Tran, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University Health Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MontrealGH</last_name>
  </overall_contact>
  <location>
    <facility>
      <name>Montreal General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G-1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>De QH Tran, MD, FRCPC</last_name>
      <phone>+15149341934</phone>
      <phone_ext>43261</phone_ext>
      <email>de_tran@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Roderick J Finlayson, MD, FRCPC</last_name>
    </contact_backup>
    <investigator>
      <last_name>De QH Tran, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2015</study_first_submitted>
  <study_first_submitted_qc>October 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2015</study_first_posted>
  <last_update_submitted>June 9, 2016</last_update_submitted>
  <last_update_submitted_qc>June 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McGill University Health Center</investigator_affiliation>
    <investigator_full_name>De Tran</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

